Department of Internal Medicine, Bassett Medical Center and Columbia University College of Physicians and Surgeons, Cooperstown, NY 13326, USA.
Am J Emerg Med. 2013 Apr;31(4):756.e1-2. doi: 10.1016/j.ajem.2012.11.011. Epub 2013 Feb 8.
Denosumab, a human monoclonal antibody to the receptor activator of nuclear factor-κB ligand, is a novel therapy to osteoporotic fracture and skeletal-related events in patients with bone metastases. Hypocalcemia is its known adverse effect, although it is generally mild and transient and usually occurs in patients with severe chronic kidney disease or end-stage renal disease. We reported a case 61-year-old woman who received a single dose of denosumab and developed severe symptomatic hypocalcemia associated with prolong QTc interval requiring hospitalization for intravenous calcium.
地舒单抗是一种针对核因子-κB 配体受体激活剂的人源单克隆抗体，是一种治疗骨质疏松性骨折和伴有骨转移患者骨骼相关事件的新型药物。低钙血症是其已知的不良反应，尽管通常为轻度和短暂的，且通常发生于严重慢性肾脏病或终末期肾病患者中。我们报告了一例 61 岁女性，单次接受地舒单抗治疗后出现严重症状性低钙血症，伴有 QTc 间期延长，需要住院静脉补钙治疗。
